Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Published Online: 2017-10-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alvaro Montaño•Amy V Kapp•Andrea Wong•Anne Hardy Bessard•Antoinette R Tan•Antoinette Tan•Antonio Gonzalez Martin•Chiun-Sheng Huang•Christelle Levy•Cristina Saura•Daniel J Maslyar•David Chan•Filippo De Braud•Gilles Romieu•Gregory Vidal•Hwei-Chung Wang•Jae Hong Seo•Jee Hyun Kim•Joo Hyuk Sohn•José Baselga•Keun Seok Lee•Laura Garcia Estevez•Leonard Seigel•Luc Dirix•Mafalda Oliveira•Mafalda Oliveira•Marc Debled•Marc Espié•Marc Espié•Mary Ann K Allison•Matthew J Wongchenko•Melody Cobleigh•Michel Velez•Michelino De Laurentiis•Mohamad Salkini•Nicholas Iannotti•Pedro Sanchez Rovira•Pier Franco Conte•Rafael Villanueva•Rebecca Dent•Rebecca Dent•Robert Figlin•Sara Hurvitz•Seock-Ah Im•Seock-Ah Im•Shaker Dakhil•Shin-Cheh Chen•Sibel Blau•Sibel Blau•Steven Isakoff•Steven J Isakoff•Stina M Singel•Sung-Bae Kim•Sung-Bae Kim•Vicente Valero•Vincent Hansen•Wai Y Chan•William Lawler•Yen-Hsun Chen
